What is Lifesci Capital’s Estimate for TARS FY2025 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Investment analysts at Lifesci Capital issued their FY2025 EPS estimates for shares of Tarsus Pharmaceuticals in a research note issued on Wednesday, February 26th. Lifesci Capital analyst C. Jubinville anticipates that the company will post earnings per share of ($1.65) for the year. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q4 2025 earnings at ($0.11) EPS.

Tarsus Pharmaceuticals (NASDAQ:TARS) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. The company had revenue of $66.41 million for the quarter, compared to the consensus estimate of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%.

Several other analysts also recently weighed in on TARS. Oppenheimer lifted their price objective on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. HC Wainwright reiterated a “buy” rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Wednesday. Barclays cut their target price on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday. The Goldman Sachs Group boosted their price target on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the stock a “neutral” rating in a research report on Friday, November 15th. Finally, Guggenheim reiterated a “buy” rating and issued a $78.00 target price (up from $75.00) on shares of Tarsus Pharmaceuticals in a report on Monday. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $61.33.

Tarsus Pharmaceuticals Stock Performance

TARS stock opened at $42.56 on Thursday. Tarsus Pharmaceuticals has a 1 year low of $20.08 and a 1 year high of $57.28. The stock has a market capitalization of $1.63 billion, a price-to-earnings ratio of -11.17 and a beta of 1.01. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The stock’s fifty day moving average is $51.31 and its two-hundred day moving average is $43.00.

Institutional Trading of Tarsus Pharmaceuticals

A number of institutional investors have recently made changes to their positions in TARS. Toronto Dominion Bank acquired a new stake in Tarsus Pharmaceuticals in the 4th quarter valued at about $105,714,000. Jennison Associates LLC increased its holdings in shares of Tarsus Pharmaceuticals by 47.2% during the third quarter. Jennison Associates LLC now owns 2,178,580 shares of the company’s stock worth $71,653,000 after purchasing an additional 698,712 shares during the period. Lord Abbett & CO. LLC raised its position in shares of Tarsus Pharmaceuticals by 115.2% in the fourth quarter. Lord Abbett & CO. LLC now owns 1,279,987 shares of the company’s stock valued at $70,873,000 after buying an additional 685,111 shares in the last quarter. Millennium Management LLC lifted its position in Tarsus Pharmaceuticals by 189.4% during the fourth quarter. Millennium Management LLC now owns 644,010 shares of the company’s stock worth $35,659,000 after purchasing an additional 421,495 shares during the period. Finally, JPMorgan Chase & Co. raised its position in Tarsus Pharmaceuticals by 2,088.8% during the third quarter. JPMorgan Chase & Co. now owns 440,167 shares of the company’s stock valued at $14,477,000 after purchasing an additional 420,057 shares in the last quarter. Institutional investors own 90.01% of the company’s stock.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.